High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

about

Current treatment methods for combination antiretroviral therapy-induced lipoatrophy of the face.

P2860

Q38130905-57BBB6F7-17B4-45ED-820A-5627E7243D4F

P2860

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

Item

http://www.wikidata.org/entity/Q58797959

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в червні 2011

@uk

name

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

@en

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

@nl

type

Item

label

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

@en

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

@nl

prefLabel

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

@en

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

@nl

P1476

High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy

@en

P2093

Alessio Baccarani

http://www.w3.org/2001/XMLSchema#string

Antonio Pedone

http://www.w3.org/2001/XMLSchema#string

Gabriella Orlando

http://www.w3.org/2001/XMLSchema#string

Marco Pignatti

http://www.w3.org/2001/XMLSchema#string

Matteo Lombardi

http://www.w3.org/2001/XMLSchema#string

P2860

Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.

Milia en plaque: a case report and review of the literature.

Hyaluronic acid fillers: a comprehensive review.

Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy

HIV facial lipoatrophy: causes and treatment options.

The role of hyaluronic acid fillers (Restylane) in facial cosmetic surgery: review and technical considerations.

Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies--consensus recommendations.

Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability.

Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.

P2888

s00266-011-9771-3

P304

180-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00266-011-9771-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Guaraldi

Giorgio De Santis

P577

2011-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21717261

http://www.w3.org/2001/XMLSchema#string

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

about

P2860

P2860

High-density Hyaluronic Acid for the Treatment of HIV-related Facial Lipoatrophy

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698